Perspectives on the safety of a JAK inhibitor in RA, PsA, and AS – Featuring Drs Wickersham, Winthrop, and Ritchlin Sponsored by AbbVie Medical Affairs

Drs. Pendleton Wickersham (Arthritis Associates PA, San Antonio, TX), Kevin Winthrop (OHSU, Portland, OR), and Christopher Ritchlin (URMC, Rochester, NY) come together to share their experiences discussing with patients the benefit-risk of a JAK inhibitor.